In recent years, first-line therapies for metastatic renal cell carcinoma (mRCC) have shifted to a combination of immune checkpoint inhibitors or a combination of antiangiogenesis tyrosine kinase ...
Patient outcomes are poor for aggressive B-cell non-Hodgkin’s lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen ...
Dana Chase, MD, discussed recent shifts in second-line endometrial cancer care, the role of molecular testing, and the potential of antibody-drug conjugates. The treatment landscape for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results